Unlock instant, AI-driven research and patent intelligence for your innovation.

Tenoxicam dispersible tablet and preparation method thereof

A technology of tenoxicam and dispersible tablets, which is applied in the direction of non-active ingredient medical preparations, medical preparations containing active ingredients, and pharmaceutical formulas, etc., can solve the problem of not using acidifiers, low bioavailability, and harmful effects on the body. Stimulation and other issues, to achieve the effect of improving bioavailability, reducing body stimulation, and reducing body stimulation

Inactive Publication Date: 2014-08-20
QINGDAO MUNICIPAL HOSPITAL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The invention provides a kind of tenoxicam dispersible tablets, which is based on the existing tenoxicam pharmaceutical preparation form or the addition of surfactants is irritating to the body, and the bioavailability is not high, or no acidifying agent is used

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tenoxicam dispersible tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Tenoxicam 20g

[0057] Lactose 300g

[0058] Cross-linked polyvinylpyrrolidone 200g

[0059] Carboxymethyl Starch Sodium 200g

[0060] Hypromellose 7g

[0061] Micronized silica gel 30g

[0062] Magnesium Stearate 15g

[0063] water 153g

[0064] 95% ethanol 100g

[0065] Made in 1000 pieces.

[0066] Preparation:

[0067] Step 1: Pass the pulverized tenoxicam and pharmaceutical excipients through a 120-mesh sieve respectively, swell the hydroxypropyl methylcellulose with hot water, stir until dissolved, and then add ethanol to make the ethanol concentration reach 80%.

[0068] Step 2: Mix tenoxicam, lactose, crospovidone, and micropowdered silica gel evenly according to the prescription amount, and add the hypromellose solution described in step 1 to make a soft material.

[0069] Step 3: Pass the soft material prepared in step 2 through an 18-mesh sieve to granulate, dry at 50°C, and have a moisture content of 2.6%, and granulate through an 18-mesh sieve.

...

Embodiment 2

[0074] Tenoxicam 20g

[0075] Lactose 300g

[0076] Cross-linked polyvinylpyrrolidone 90g

[0077] Carboxymethyl Starch Sodium 200g

[0078] Hypromellose 3.5g

[0079] Citric acid 100g

[0080] Micronized silica gel 25g

[0081] Magnesium Stearate 7.5g

[0082] water 175

[0083] 95% ethanol 114g

[0084] Made in 1000 pieces.

[0085] Preparation:

[0086] Step 1: Pass the pulverized tenoxicam and pharmaceutical excipients through a 120-mesh sieve respectively, swell the hydroxypropyl methylcellulose with hot water, stir until dissolved, and then add ethanol to make the ethanol concentration reach 80%. Another 3.5 g of the above-mentioned hydroxypropyl methylcellulose solution was taken, 175 g of water was added, citric acid was added, and the mixture was evenly mixed.

[0087] Step 2: The prescription amount of tenoxicam and the citric acid solution in step 1 are embedded in fluidized bed acid solution, and then mixed with the prescription amount of lactose, cross-l...

Embodiment 3

[0093] Tenoxicam 20g

[0094] Cross-linked polyvinylpyrrolidone 350g

[0095] Carboxymethyl Starch Sodium 250g

[0096] Hypromellose 3.5g

[0097] Citric acid 100g

[0098] Micronized silica gel 15g

[0099] Magnesium Stearate 7.5g

[0100] water 189

[0101] 95% ethanol 100g

[0102] Made in 1000 pieces.

[0103] The preparation method is the same as in Example 2.

[0104] Implementation 3 increased the content of cross-linked polyvinylpyrrolidone and sodium starch glycolate, and the dispersibility of the dispersible tablets met the requirements of the 2010 edition of the Pharmacopoeia, and the dissolution rate was better.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a tenoxicam dispersible tablet as well as a preparation method and an application of the tablet. The tenoxicam dispersible tablet consists of the following components in percentage by weight: 2-20% of tenoxicam, 10-50% of filling agent, 10-50% of disintegrating agent, 10-60% of acidifying agent, 0.1-20% of binding agent and 0.1-30% of lubricant and flow aid. Compared with an ordinary tablet, the tenoxicam dispersible tablet disclosed by the invention does not contain a surfactant, is good in solubility, dispersibility and disintegration, and can be completely disintegrated within one minute. The tenoxicam dispersible tablet prepared by using the method is high in dissolution rate, good in bioavailability, can be quickly distributed in vivo, is stable in quality and good in taste, and the preparation method is simple and feasible and applicable to industrial production.

Description

field of invention [0001] The invention relates to the field of chemical pharmacy, in particular to a tenoxicam dispersible tablet and a preparation method thereof. Background of the invention [0002] Arthritis is a common and chronic disease, in which osteoarthritis and rheumatoid arthritis are the main forms. According to reports, about 18% of the people in our country suffer from some form of arthritis, and the number of cases exceeds 200 million. Arthritis is a serious threat to human health, affecting the life and work of patients, making some patients unable to take care of themselves and lose their ability to work. Some patients have restricted activities, joint swelling, stiffness and pain, and severe joint permanent deformation, which is an important cause of disability in the elderly, so timely treatment is required. [0003] Tenoxicam (Tenoxicam), CA accession number 59804-37-4, chemical name 4_hydroxy_2_methyl-N-(2-pyridyl)-2H-thieno[2,3-e]- l,2-thiazine-3-ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K47/12A61K47/02A61K31/542A61P19/02A61P29/00
Inventor 沈红卫于珂
Owner QINGDAO MUNICIPAL HOSPITAL